Screener
Halozyme Therapeutics HALO Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's finite-lived intangible assets - expected amortization expense (year one)?
- Halozyme Therapeutics (HALO) reported finite-lived intangible assets - expected amortization expense (year one) of $60.62M in Q2 2026.
- How has Halozyme Therapeutics's finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
- Halozyme Therapeutics's finite-lived intangible assets - expected amortization expense (year one) increased by 66.9% year-over-year, from $36.31M to $60.62M.
- What does finite-lived intangible assets - expected amortization expense (year one) mean?
- This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.
Ask your AI about Halozyme Therapeutics's finite-lived intangible assets - expected amortization expense (year one).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude